Abdallah Mahamoud

TL;DR: Inhibition of bacterial efflux mechanisms appears to be a promising target in order to increase the intracellular concentration of antibiotics that are expelled by efflux pumps, restore the drug susceptibility of resistant clinical strains, and reduce the capability for acquired additional resistance.

TL;DR: Different strategies could be proposed to bypass the bacterial membrane barrier, comprising influx and efflux mechanisms, in order to restore the activity of antibiotics against resistant bacteria.

TL;DR: Various quinoline derivatives significantly increase the intracellular concentration of chloramphenicol as reported with other inhibitors, thereby suggesting the inhibition of the drug transport by AcrAB-TolC pump, which is fully active in the clinicaly resistant isolates investigated.

TL;DR: Alkylaminoquinolines are shown to be capable of restoring susceptibilities to structurally unrelated antibiotics in clinical isolates of MDR Gram-negative bacteria and acting as an inhibitor of the AcrAB-TolC efflux pump.

TL;DR: 2,8-dimethyl-4-(2′-pyrrolidinoethyl)-oxyquinoline restores noticeable drug susceptibility to resistant clinical strains and inhibits the efflux pump mechanism and improves the activity of structurally unrelated antibiotics on multidrug-resistant E. aerogenes and K. pneumoniae isolates.